BCD-217
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for BCD-217, covering 2023-02-10 to 2025-07-08. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma [Phase 3]